Joby Aviation closes $591 million stock offering with full underwriter option
Walmart Inc. NYSE:WMT, the $820 billion market cap retail giant with a ’GOOD’ financial health rating according to InvestingPro, saw Executive Vice President Kathryn J. McLay sell 4,000 shares of the company’s common stock on September 19, 2025, at a price of $103.83, totaling $415,320. The stock has delivered an impressive 31% return over the past year, while maintaining its 53-year streak of consistent dividend payments.
Following the transaction, McLay directly owns 1,048,455.036 shares of Walmart Inc.
The sale was executed under a Rule 10b5-1 trading plan, adopted by McLay during an open trading window and disclosed by Walmart on Form 8-K on November 22, 2024.
The transaction was signed on behalf of Kathryn J. McLay by Dirk Gardner, by power of attorney.
In other recent news, Walmart has expanded its pharmacy delivery service to include refrigerated and reconstituted medications, making it the first retailer to offer such prescriptions alongside groceries in a single online order. This service now includes temperature-sensitive medications like insulin, which account for over 30% of Walmart Pharmacy sales. On the analyst front, BofA Securities has raised its price target for Walmart stock to $125, maintaining a Buy rating after investor meetings with key executives. Similarly, UBS continues to support its Buy rating with a $110 price target, following a visit to Walmart’s apparel pop-up shop in New York City. Bernstein has reiterated an Outperform rating with a $117 target, highlighting potential growth in e-commerce and retail media. Additionally, Walmart’s Executive Vice President, Donna Morris, has set a pre-arranged stock trading plan for asset diversification and financial planning purposes. These developments reflect ongoing strategic moves and analyst confidence in Walmart’s growth potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.